Latest News

29 February 2024

Honouring Rare Disease Day: The Battle Against Multiple Myeloma and AL Amyloidosis

Today, on Rare Disease Day, we reflect on the courage and resilience of those facing the challenges of rare medical conditions.

Read article +
1 February 2024

HaemaLogiX announces appointment of Laurence Turka, M.D. as a Non-Executive Director

HaemaLogiX Ltd, a clinical stage biotech, is pleased to announce the appointment of Laurence Turka, M.D. to its board as a non-executive director.

Read article +
31 January 2024

HaemaLogiX appoints haematologist Angela Dispenzieri, M.D. to its Scientific Advisory Board

HaemaLogiX Ltd, a clinical stage biotech, is pleased to announce the appointment of Professor of Medicine and of Laboratory Medicine and Pathology Angela Dispenzieri, M.D. to its Scientific Advisory Board (SAB).

Read article +
16 January 2024

HaemaLogiX announces issuance of South Korean patent for KMA.CAR-T

HaemaLogiX’s South Korean patent 'Kappa Myeloma Antigen Chimeric Receptors and Uses Thereof' was granted in South Korea on 5 January 2024.

Read article +
4 January 2024

Dr. John Cullity Appointed Chairman of HaemaLogiX

The Board of HaemaLogiX Ltd has appointed non-executive director, Dr, John Cullity, as Chairman of the Company to hold office through the next phase of the Company transformation, which was initiated earlier this year with the announcement of our new CEO.

Read article +